"Mad Money" host Jim Cramer gives his take on what to do with Whole Foods ahead of next week's earnings.» Read More
How unrest in South America impacts oil prices and the U.S. economy, with Dennis Gartman of the Gartman Letter.
The "Fast Money" traders offer up their top four tech trades.
It's March Madness, "Mad Money" style! Jim Cramer gives his top NCAA teams and pairs them with his favorite stocks of the region.
Jim Cramer is seeing an unusual trend in the market lately, which has set these stocks on fire.
The volatility should be a slap in the face to investors, who should take a look at their portfolios, KKM Financial's Jeff Kilburg said.
The Fast Money traders share their final trades of the day.
The Fast Money traders take a look at today's biggest market movers.
Greg Butterfield, Vivint Solar CEO, discusses the impact oil is having on the solar business.
CNBC's Eric Chemi outlines stocks with historically strong performances during the March Madness period.
Why UBS cut its price target on Microsoft to $49 from $52 in light of currency headwinds, with Brent Thill, UBS managing director and senior analyst.
Dissecting oil's impact on today's trade, with the Fast Money traders.'
Check back here on cnbc.com/pro for full coverage of the Fast Money Madness stock tournament.
A stock brawl on Disney featuring a bullish Robert Luna, Surevest Wealth, versus a bearish David Trainer, New Constructs.
A handful of stocks have benefited after the Cardiology and CME Conferences. CNBC's Meg Tirrell names which ones to keep an eye on including AstraZeneca and Edwards Lifesciences.
CNBC's Eric Chemi discusses why the market performs well during March Madness.
Netflix, whose shares are up 22 percent on the year to $419, may soon show that its stock does shrink sometimes.
Wall Street is giving five big reasons for why the price of oil is headed lower. You may have heard two but at least two are surprising.
CNBC's Jim Cramer explains why he is watching Harman Intl. and Hanesbrands. Those are both big winners, says Cramer.
Jim Cramer explains why he likes Regeneron and Amgen, and is keeping an eye on shares of Mobileye and Edwards Lifesciences.
Analyst Dan Fitzpatrick tells CNBC he's getting fatigued with the fixation on the Fed.